

[View this email in your browser](#)

Public Newsletter Jan-Aug 2021



Mobilise-D accelerates breakthrough innovations in digital health monitoring to assess patients' daily life mobility, focusing on different conditions that often affect mobility (COPD, PD, MS, hip fracture), with the goal to improve follow-up and personalized care of patients.

600 participants enrolled in the Clinical Validation Study (CVS) 🎉

Mobilise-D reached a major milestone in the first week of September as we enrolled participant number 600 in the CVS. This means that we have reached 25% of the full sample size of 2400 participants.

“This is more than we could hope for when we started in April”, says Prof. MD. Clemens Becker, our CVS lead. He continues, “Now, as the summer breaks are coming to an end, all sites are picking up speed. We know how hard it is and how much effort goes into the assessment. The entire consortium is working towards an united goal and it is worth the effort. Great pleasure and honor to work with you all.”



Mobilise-D and IDEA-FAST join forces

From 2021 onwards, Mobilise-D and IDEA-FAST join forces to increase the impact and the benefits of digital health technologies developed by both IMI projects.



The European Medicines Agency support for Mobilise-D: Follow-up

The EMA published a second letter of support, informing the wider community on our progress with digital mobility outcomes and regulatory approval. Read more [HERE](#).



It's a kind of magic: The validation study has been Mobilise-D against all odds

We invited one of our Mobilisers, Kirsty Scott, to share some of the daunting yet exciting experiences of being part of the team and how they are managing to conduct the Technical Validation Study (TVS) in Mobilise-D in COVID-19 times. Read more [HERE](#).


IMI article about our Digital Health Catalyst initiative

The Digital Health Catalyst (DHC) was created by Mobilise-D and IDEA-FAST in response to the growing need for research and applications in the area of real-world digital measures. You can find the link to the IMI article [HERE](#).



Mobilise-D Videos

See all our videos on our [YouTube channel](#).



Mobilise-D Publications

See all our publications [HERE](#).

💡 In the Spotlight Series 💡



Episode 2: An insight into public engagement - interview with PhD student Cameron Kirk

Here you get to know our Mobiliser Cameron Kirk, and what drove him to apply for the INSIGHTS doctoral public lecture prize at Newcastle University, UK. Read the episode [HERE](#).



Episode 3: Making a difference in people's lives - Silvia Del Din awarded a NUAcT fellowship

Get to know our Mobiliser Silvia, her NUAcT fellowship, and her perspective on how remote monitoring can revolutionize healthcare. Read the episode [HERE](#).



Episode 4: The Cyclone Challenge - Mobiliser raising money for PD UK

Our Mobiliser Alison Yarnall wanted to raise money for Parkinson's Disease UK. Read our latest episode to find out how she did it and why she selected PD UK in particular [HERE](#).

Real World Stories Series



Episode 2: - It's great to exercise myself together with my groups

Being able to function in daily life is a major factor for good health and quality of life. So how can we inspire our seniors to be more physically active, staying fit and healthy? Read our interview with instructor Lise [HERE](#).



Episode 3: When life gives you lemons, make lemon drizzle cake

Patrick has advanced Multiple Sclerosis (MS) which affects his daily life mobility to a great extent. Read our interview with him to find out how he copes with the disabilities caused by MS [HERE](#).

Key challenges in the use & development of digital endpoints from a health technology assessment (HTA) perspective

Digital endpoints offer a great potential to be considered in the HTA framework. So far, however, there is no institutional way in. IMI Neuronet hosted a meeting where several important issues

were discussed in a working group on HTA and regulatory interactions. Read the HTA expert's perspectives on several important issues [HERE](#).



Recent Tweet



Mobilise-D
@Mobilise_D



YESS!!! Our [#ClinicalValidationStudy](#) has recently passed **600** participants - which means we have reached 25% of the full [#CVS](#) sample size 🎉

[#MobiliseD](#) [#digitalhealth](#) [#wearables](#) [#sensors](#)
[#mobility](#) [#DMOs](#) [@IMI_JU](#) [@EFPIA](#) [@ERTglobal](#)
[@McRobertsNL](#)



11:22 AM - Sep 7, 2021 · Twitter Web App

||| View Tweet activity

8 Retweets 18 Likes



Follow us on Social Media!

[@Mobilise_D](#)



Mobilise-D has received funding from IMI 2 Joint Undertaking under grant agreement No. 820820. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Copyright © 2021 Mobilise-D, All rights reserved.

Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

